Complex Statistical & Economic Analysis

Direct Treatment Comparison

Meta-analysis (MA) is a statistical technique which pools data from published studies to provide a precise estimate of pair-wise treatment effect size between two interventions. MAs typically follow the completion of a systematic literature review and are widely used throughout the scientific community to report comparative efficacy and safety of medical treatments or diagnostic tests and tools. By pooling the estimate of the effect size across multiple trials, MAs can provide a stronger statistical power compared to individual trials. MAs can also be used to understand possible correlations between trial endpoints. Evidinno’s research team have abundant experience conducting such analyses and conforms to recommended guidelines for conducting MA, including the Cochrane Handbook for Systematic Reviews of Interventions.

Indirect Treatment Comparisons

Indirect treatment comparison (ITC) is a more complex form of MA that is used to compare the efficacy and/or safety of interventions that have only been directly compared to a common comparator (a placebo or a different intervention), but not to each other.  Evidinno’s research team has conducted and published a large number of ITCs and conforms to recommended guidelines for conducting ITC, including the Cochrane Handbook for Systematic Reviews of Interventions.

Surrogate Endpoint Analysis

It happens often in oncological trials that a specific endpoint is the gold standard; however, data on that particular endpoint may take significant amount of time to materialize, and thus reliance on maturation of such data could delay the introduction of possibly beneficial treatments. Additionally, many randomized controlled trials have also failed to demonstrate a benefit in long-term study endpoints for investigational drugs, despite improvements in other endpoints that may become available sooner in the course of the study. In such cases, a surrogate endpoint analysis is a very useful set of tools that can help define and assess the validity as well as robustness of a surrogacy relationship between two endpoints. An example of such an analysis would be the investigation of the surrogacy relationship between overall survival and progression-free survival in oncological studies. Evidinno’s expert team of statisticians and clinical epidemiologists have abundant experience conducting and publishing surrogacy analysis across therapeutic areas and can help achieve our client’s objectives.

Economic Analyses (BIM, CEA, CUA, CMA)

Economic analyses provide critical insights into the value of healthcare interventions by quantifying costs and outcomes to inform decision-making. Our team of seasoned health economists develops budget impact models (BIMs), cost-effectiveness analyses (CEAs), cost-utility analyses (CUAs), and cost-minimization analyses (CMAs) to evaluate economic implications and clinical benefits. These models are built using rigorous, evidence-based methods and are designed to meet the requirements of health technology assessment (HTA) agencies, payers, and policymakers, supporting reimbursement submissions and strategic market access planning. In addition, we offer model adaptations for different regions globally, tailoring inputs and assumptions to reflect local clinical practice patterns, healthcare costs, and policy environments.
Have a research question? Click here to learn how we can help.